Author:
Dzitko Katarzyna,Paneth Agata,Plech Tomasz,Pawełczyk Jakub,Węglińska Lidia,Paneth Piotr
Abstract
ABSTRACTThis article reports anti-Toxoplasma gondiiactivity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible antiparasitic effects at nontoxic concentrations for the host cells, with an experimentally determined 50% inhibitory concentration (IC50) at least 30 times better than that of the known chemotherapeutic agent sulfadiazine. Purine nucleoside phosphorylase was defined as the probable target for anti-Toxoplasmaactivity of the tested compound. These results provide the foundation for future work to develop a new class of medicines to better treat toxoplasmosis.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference18 articles.
1. Antibiotics for human toxoplasmosis: a systematic review of randomized trials;Rajapakse;Pathog. Glob. Health,2013
2. Prevention and treatment of pneumocystis pneumonia;Masur;N. Engl. J. Med.,1992
3. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine;Dannemann;The California Collaborative Treatment Group. Ann. Intern. Med.,1992
4. Opportunistic nosocomial infections. Treatment and developmental therapeutics;Georgiev;Toxoplasmosis. Med. Res. Rev.,1993
5. Recent advances in the management of AIDS-related opportunistic infections;Lane;Ann. Intern. Med.,1994
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献